| Bioactivity | DPO-1 is a potent inhibitor of the voltage-gated potassium channel subtype Kv1.5 and a blocker of ultrarapid delayed rectifier potassium current. DPO-1 prevents atrial arrhythmia[1][2]. | |||||||||
| Name | DPO-1 | |||||||||
| CAS | 43077-30-1 | |||||||||
| Formula | C22H29OP | |||||||||
| Molar Mass | 340.44 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Lagrutta A, et al. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. [2]. Stump GL, et al. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther. 2005 Dec;315(3):1362-7. |